Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first healthcare company to top a $1 trillion valuation, perhaps as early as this year.
Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.
This was the stock's second consecutive day of gains.
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
2don MSN
Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential ...
Lilly gave hopeful income projections for 2025 ranging from $58 billion to $61 billion, therefore showing a midpoint rise of ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, ...
In a report released today, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback